|Bid||36.66 x 2900|
|Ask||36.65 x 2200|
|Day's Range||36.41 - 36.74|
|52 Week Range||33.97 - 46.47|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||16.89|
|Earnings Date||Oct 29, 2019|
|Forward Dividend & Yield||1.44 (3.97%)|
|1y Target Est||41.90|
South San Francisco-based Allogene is taking a different approach to cell therapy for cancer by producing so-called allogenic cell therapies.
Economists Say Spend $2 Trillion to Combat Next Recession In another sign that economics as the study of scarcity and choice has completely lost its way, economists, whose title suggests that they study scarcity and choice and the art of economizing resources, are in general agreement, according to Reuters, that in order to save the […]The post Market Morning: Economists Say Spend More, Viagra For Leukemia, Aerospace Mergers appeared first on Market Exclusive.
LOS ANGELES , Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca ...
–Abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study–
A biotech company that started in Israel 21 months ago and moved to San Francisco this year wants to raise $70 million through an initial public offering to tackle one of the hottest areas of drug development. Fourteen-employee 89bio Inc. stated in a Securities and Exchange Commission filing Friday that it plans to use the cash to complete mid-stage clinical trials of its signature drug against the fatty liver disease known as nonalcoholic steatohepatitis, or NASH, and severe hypertriglyceridemia as well as for drug manufacturing. NASH has attracted deep-pocketed drug companies such as Foster City-based Gilead Sciences Inc. (NASDAQ: GILD), South San Francisco's NGM Biopharmaceuticals Inc. (NASDAQ: NGM), Pfizer Inc. (NYSE: PFE) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) and an army of smaller companies, such as South San Francisco's Akero Therapeutics Inc. (NASDAQ: AKRO).
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
With more and more trading platforms and the growing allure of low-to-no-fee brokerages, new traders are confronted with a deluge of options when it comes to trading and investing. Cash flow is commonly broken into three separate segments: operating cash flow, investing cash flow and financing cash flow.
J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
Goldman Sachs lowers price target for Clovis' (CLVS) shares taking into account the risk of lower future revenues due to rising competition in the PARP inhibitor segment.
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hikes were more than twice the rate of medical inflation and were not supported by any new clinical evidence, the Institute for Clinical and Economic Review (ICER) said in the analysis.
AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hikes were more than twice the rate of medical inflation and were unsupported by any new clinical evidence, the Institute for Clinical and Economic Review (ICER) said in the analysis.
Shares of Akcea Therapeutics rocketed in higher-than-average volume on Monday after the Ionis Pharmaceuticals affiliate announced a licensing deal with Dow Jones component Pfizer.
Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.
Akcea shares soar after the company announces a licensing agreement with Pfizer for its treatment for people with certain cardiovascular and metabolic diseases.